一、药品注册证书主要信息 证券代码：300723 证券简称：一品红 公告编号：2025-058 一品红药业集团股份有限公司 关于全资子公司获得注射用硫酸艾沙康唑注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于注射用硫酸艾沙 康唑的《药品注册证书》，现将有关事项公告如下： 药品通用名称：注射用硫酸艾沙康唑 英文名/拉丁名：Isavuconazonium Sulfate for Injection 主要成份：硫酸艾沙康唑 剂 型：注射剂 注册分类：化学药品 4 类 规 格：0.2g（按 C22H17F2N5OS 计） 药品注册标准编号：YBH20082025 药品有效期：18 个月 申请事项：药品注册（境内生产） 药品批准文号：国药准字 H20255224 药品批准文号有效期：至 2030 年 8 月 25 日 二、注射用硫酸艾沙康唑相关情况 包装规格： 1 瓶/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管 ...

注射用硫酸艾沙康唑主要用于治疗成人患者侵袭性曲霉病、侵袭性毛霉病感染。 人民财讯9月1日电，一品红（300723）9月1日晚间公告，公司全资子公司广州一品红制药有限公司近日 收到国家药监局核准签发的关于注射用硫酸艾沙康唑的《药品注册证书》。 ...

一品红公告，全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于注射 用硫酸艾沙康唑的《药品注册证书》。注射用硫酸艾沙康唑适应症为：主要用于治疗成人患者下列感 染：侵袭性曲霉病；侵袭性毛霉病。 ...

Core Viewpoint - The weight loss drug sector has shown a significant increase, with a rise of 2.99% as of September 1, ranking it seventh among concept sectors, driven by strong performances from several stocks [1][2]. Group 1: Sector Performance - The weight loss drug sector saw 48 stocks increase in value, with notable gainers including Baihua Pharmaceutical (up 10.91%), Dezhan Health (up 10.00%), and Health元 (up 9.98%) [1][2]. - Conversely, stocks such as Sichuan Shuangma, Nawei Technology, and Deyuan Pharmaceutical experienced declines, with drops of 3.73%, 3.61%, and 1.64% respectively [1][2]. Group 2: Capital Flow - The weight loss drug sector attracted a net inflow of 1.528 billion yuan, with 35 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflows [2][3]. - Leading the net inflow was Heng Rui Pharmaceutical, which saw a net inflow of 524 million yuan, followed by Fosun Pharmaceutical (233 million yuan), Health元 (213 million yuan), and Yi Pin Hong (128 million yuan) [2][3]. Group 3: Stock Specifics - Health元, Dezhan Health, and Baihua Pharmaceutical had the highest net inflow ratios at 28.67%, 26.23%, and 16.34% respectively [3]. - Specific stock performances included Heng Rui Pharmaceutical (up 3.20% with a turnover rate of 1.37%), Fosun Pharmaceutical (up 6.38% with a turnover rate of 4.71%), and Health元 (up 9.98% with a turnover rate of 3.05%) [3][4].

Group 1 - The chemical pharmaceutical sector increased by 3.54% on September 1, with Maiwei Biotech leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] - Notable gainers in the chemical pharmaceutical sector included Maiwei Biotech, which rose by 20.00% to a closing price of 57.60, and Xingqi Eye Medicine, which increased by 14.65% to 77.54 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 1.245 billion yuan from main funds, while retail funds experienced a net outflow of 41.1167 million yuan [2] - The top stocks by main fund inflow included Heng Rui Medicine with 474 million yuan and Fuxing Medicine with 256 million yuan [3] - Conversely, stocks like Duorui Medicine and ST Suwu experienced significant declines, with Duorui Medicine down 9.36% to 41.17 [2][3]

行业方面，创新药板块的产品收入和对外授权过去三年来一直保持着较快增长，今年以来大额BD交易 频出，推动创新药行情呈现出向整体板块扩散趋势，医保目录调整将首度纳入商保创新药目录，从半年 报情况来看，创新药板块仍保持收入高增长并不断减亏扭亏。 创新药概念1日盘中走势活跃，截至发稿，迈威生物20%涨停续创新高，一品红、智翔金泰、海辰药业 等涨超10%，康辰药业、长春高新涨停，百济神州涨近9%，药明康德涨逾5%。 中金表示，国内工程师红利、丰富临床资源和支持性政策多边加持下，国产创新药已逐渐从跟随时代走 向FIC、BIC创新。经历几年耕耘，国内品种商业化放量，并有望受益于支付端政策改革，创新药企盈 利能力提升；在研管线数据优异，大额BD持续达成。进入2.0时代的创新药产业已经逐步完成质的提 升。下半年10月中旬围绕ESMO会议前后相关临床数据读出与BD有望带来板块新一轮投资机遇。 此外，2025年以来，商业医疗险相关政策持续推进，有望加速医疗体系支付改革，缓和供需矛盾同时， 加速支持国产创新。近期育儿补贴相关政策的推行有望改善远期人口压力，并一定程度刺激婴幼儿相关 消费。进入下半年，伴随着财政政策的加码，国内医疗设备 ...

Core Viewpoint - The stock of Yipinhong has experienced significant fluctuations, with a year-to-date increase of 299.24%, but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of August 26, Yipinhong's stock price was 68.11 CNY per share, with a market capitalization of 30.765 billion CNY [1]. - The stock has seen a recent decline of 4.79% over the last five trading days and 8.85% over the last twenty trading days, despite a 31.41% increase over the last sixty days [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yipinhong reported a revenue of 584 million CNY, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.5422 million CNY, a decrease of 258.30% [2]. - The company has distributed a total of 335 million CNY in dividends since its A-share listing, with 151 million CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of July 31, the number of Yipinhong's shareholders increased to 21,300, a rise of 24.22%, while the average circulating shares per person decreased by 19.50% to 19,650 shares [2]. - Among the top ten circulating shareholders, E Fund Medical Healthcare Industry Mixed A (110023) is the eighth largest shareholder, holding 4.3661 million shares as a new entrant [3].

人民财讯8月25日电，一品红（300723）8月25日晚间公告，公司全资子公司一品红制药收到国家药品监 督管理局核准签发的关于草酸艾司西酞普兰滴剂的《药品注册证书》。草酸艾司西酞普兰滴剂适应症 为：治疗抑郁症，治疗伴有或不伴有广场恐怖症的惊恐障碍。公司获批的草酸艾司西酞普兰滴剂以化学 药品3类申报注册，视同通过一致性评价。据米内网数据，2024年艾司西酞普兰在中国城市和县级公立 医院的销售规模约为18.8亿元。 ...

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its drug, Escitalopram Oxalate Drops, which is indicated for the treatment of depression and panic disorder with or without agoraphobia [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Escitalopram Oxalate Drops [1] - The approved indication for the drug includes treatment for depression and panic disorder, with or without agoraphobia [1] Group 2: Mechanism of Action - Escitalopram is the S-enantiomer of racemic citalopram, and its antidepressant effect is believed to be related to the inhibition of serotonin (5-HT) reuptake in the central nervous system, thereby enhancing serotonergic activity [1] Group 3: Market Potential - The drug was registered as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] - According to data from Minet, the sales scale of Escitalopram in urban and county-level public hospitals in China is projected to be approximately 1,879.76 million RMB in 2024 [1]

一品红药业集团股份有限公司 关于全资子公司获得草酸艾司西酞普兰滴剂注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于草酸艾司西酞普 兰滴剂的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：草酸艾司西酞普兰滴剂 英文名/拉丁名：Esicitalopram Oxalate Drops 主要成份：草酸艾司西酞普兰 剂 型：口服溶液剂 注册分类：化学药品 3 类 证券代码：300723 证券简称：一品红 公告编号：2025-057 上市许可持有人地址：广州市经济技术开发区东区东博路 6 号 生产企业：广州一品红制药有限公司 规 格：15ml:300mg（按 C20H21FN2O 计） 药品注册标准编号：YBH19462025 药品有效期：18 个月 申请事项：药品注册（境内生产） 包装规格： 1 瓶/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合 ...